{"id":470262,"date":"2025-06-06T00:00:00","date_gmt":"2025-06-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0004-2025-biopharma-chronic-obstructive-pulmonary-disease-access-reimbursement-access-reimbursement-chronic\/"},"modified":"2026-03-31T10:26:03","modified_gmt":"2026-03-31T10:26:03","slug":"acreim0004-2025-biopharma-chronic-obstructive-pulmonary-disease-access-reimbursement-access-reimbursement-chronic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0004-2025-biopharma-chronic-obstructive-pulmonary-disease-access-reimbursement-access-reimbursement-chronic\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Chronic Obstructive Pulmonary Disease (US)"},"content":{"rendered":"<p>The dynamics within the <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>, and <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr> drug classes will continue to shape the U.S. <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> market, as will the market entry of Verona\u2019s nebulized <abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>-3\/<abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>-4 inhibitor Ohtuvayre and multiple biologics, including Sanofi \/ Regeneron\u2019s <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-4 \/ <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-13 inhibitor Dupixent. The dominance of branded <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s (e.g., GlaxoSmithKline\u2019s Advair, AstraZeneca\u2019s Symbicort) will likely decline further as new generic \/ branded generic agents continue to launch. In addition, the earlier-line use of <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s will create uptake challenges for Boehringer Ingelheim\u2019s Spiriva. Ohtuvayre could compete with existing <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr> and <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr> therapies for certain subpopulations with moderate to severe <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>, while Dupixent could provide a treatment option for severe <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> patients on maximal inhaled therapy. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> agents will face increasing challenges as they strive to retain \/ gain favorable formulary position and market uptake.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which key <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> therapies (e.g., <abbr data-abbreviation-entity=\"8391\" title=\"GlaxoSmithKline\">GSK<\/abbr>\u2019s Trelegy, Boehringer Ingelheim\u2019s Stiolto) have favorable formulary placement, and how do payers manage the use and costs of these therapies?<\/li>\n<li>How do reimbursement restrictions affect physicians\u2019 prescribing of <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s, Spiriva, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s, and Dupixent for <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>?<\/li>\n<li>How do physicians anticipate using <abbr data-abbreviation-entity=\"8391\" title=\"GlaxoSmithKline\">GSK<\/abbr>\u2019s Nucala, Sanofi \/ Regeneron\u2019s itepekimab, and Chiesi\u2019s tanimilast for <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>, and how do payers expect to cover these therapies on commercial plans?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<div>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW92978545 BCX8 round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW92978545 BCX8 round-bullets\">\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<div>\n<div>\n<p style=\"\"><strong>Primary research:<\/strong>\u00a0Survey of 140 U.S. primary care physicians and pulmonologists; survey of 30 U.S. managed care organization pharmacy and medical directors<\/p>\n<\/div>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by commercial plans covering more than 165 million lives nationally and Medicare Part D plans covering up to 37.5 million lives.<\/p>\n<div>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<\/div>\n<\/div>\n<p><strong>Key drugs<\/strong>: Trelegy, Spiriva, Stiolto, Breztri, Dupixent, Symbicort, Anoro, Advair, Ohtuvayre, Nucala, itepekimab, tanimilast.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-470262","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/470262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/470262\/revisions"}],"predecessor-version":[{"id":575780,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/470262\/revisions\/575780"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=470262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}